Objective to detect the ABL point mutations in chronic myeloid leukemia (CML) patients treated with imatinib by denaturing high-performance liquid chromatography (DHPLC).
目的应用变性高效液相色谱(DHPLC)检测伊马替尼治疗后慢性髓性白血病(CML)患者ABL激酶区点突变。
Screening the mutations and polymorphisms by denaturing high-performance liquid chromatography(DHPLC) and DNA sequencing Results: 1.
应用变性高效液相色谱（DHPLC）分析及直接基因测序筛查突变和多态。
应用推荐